First-line braf/mek inhibitors versus anti-pd-1 monotherapy in brafv600-mutant advanced melanoma patients: a propensity-matched survival analysis

HIGHLIGHTS

• who: Jesper Breeschoten from the Dutch InstituteVU University, Geert Grooteplein Zuid, Nijmegen GA, The Netherlands have published the research: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis, in the Journal: (JOURNAL) of 30/Nov/2020
• what: The authors compare OS of BRAF/MEK inhibitors and anti-PD-1 monotherapy in BRAF-mutant advanced melanoma patients, and_(2) use propensity score matching to determine the overall survival in the BRAF/MEK inhibitors vs. anti-PD-1 monotherapy groups after matching. Based on the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.